We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MP BIOMEDICALS LLC

MP Biomedicals manufactures and sells a comprehensive line of in-vitro diagnostics solutions to hospitals and clinica... read more Featured Products: More products

Download Mobile App





MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)
Image: The MP Biomedicals team at MEDICA 2022 (Photo courtesy of MP Biomedicals)

MP Biomedicals (Eschwege, Germany) is exhibiting its wide product portfolio of POC, screening and confirmatory tests, backed by a range of testing methods that aid in the diagnosis, detection, and recovery from diseases, at MEDICA 2022.

At this year’s edition of MEDICA, MP Biomedicals is exhibiting the AutoBlot System 36, an intelligent Western Blot processor that enables automated washing and incubation of up to 36 assay strips per run at a pre-selected temperature. The AutoBlot System 36 helps to satisfy Immunoblot needs by minimizing human error, increasing productivity and delivering accurate and consistent results. MP Biomedicals is also showcasing its innovative diagnostic tests such as the Rapid SARS-CoV-2 Antigen Test Card, an IVD test for private use to detect SARS-CoV-2 antigens from anterior nasal swabs, alongside the Rapid 2019-nCoV IgG/IgM Combo Test Card, which is an immunochromatography based one-step in vitro test designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV,SARS-CoV-2) in human serum, plasma, or whole blood.

MP Biomedicals is also highlighting its POC testing and screening solutions for the qualitative assessment of drugs and their metabolites in human urine and saliva. Visitors to the MP Biomedicals booth at MEDICA 2022 can gain insights into the MP Diagnostics HIV BLOT 2.2 qualitative enzyme immunoassay for the in vitro detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. HIV BLOT 2.2 is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures such as the Enzyme-Linked Immunosorbent Assay (ELISA). Also on display at the event is the MP Diagnostics MULTISURE HIV 1/2 Confirmatory Test for use as a rapid confirmatory test to detect and differentiate antibodies specific to HIV-1 gp120, HIV-1 gp41, HIV-1 p24 and HIV-2 gp36, HIV-2 gp105 antigens in human serum or plasma.

Related Links:
MP Biomedicals

New
Gold Member
Chagas Disease Test
CHAGAS Cassette
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
PROM Test
AMNIOQUICK DUO
New
FAP Immunoassay
Quantikine QuicKit Human FAP ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The test could be a game changer for people with some of the most aggressive forms of cancer (Photo courtesy of UNE)

Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer

Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.